{"title":"Management of Guillain-Barré syndrome (GBS).","authors":"A F Hahn","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>GBS is an acute immune-mediated neuropathy which, in one-third of cases, leads to total paralysis requiring ICU admission for assisted ventilation and management of autonomic cardiovascular instability. The management can be challenging and even with most expert care and modern ICU facilities the mortality remains at 5-8%. This chapter gives an outline of the natural history and pathophysiology of the condition with emphasis on newer concepts. Guidelines are given for the management of patients prior to and during the admission to an ICU by highlighting the potential complications. An up-to-date account is given on the specific immunomodulatory therapies.</p>","PeriodicalId":77030,"journal":{"name":"Bailliere's clinical neurology","volume":"5 3","pages":"627-44"},"PeriodicalIF":0.0000,"publicationDate":"1996-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical neurology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
GBS is an acute immune-mediated neuropathy which, in one-third of cases, leads to total paralysis requiring ICU admission for assisted ventilation and management of autonomic cardiovascular instability. The management can be challenging and even with most expert care and modern ICU facilities the mortality remains at 5-8%. This chapter gives an outline of the natural history and pathophysiology of the condition with emphasis on newer concepts. Guidelines are given for the management of patients prior to and during the admission to an ICU by highlighting the potential complications. An up-to-date account is given on the specific immunomodulatory therapies.